Don’t miss the latest developments in business and finance.

Jubilant Life Sciences extends fall on USFDA warning letter

The stock has tanked over 15% in past two trading sessions on the Bombay Stock Exchange.

Image
SI Reporter Mumbai
Last Updated : Dec 06 2013 | 10:45 AM IST
Jubilant Life Sciences is trading lower by 5% at Rs 120, extending its previous day’s 10% fall, after the company said that US drug regulator has issued a warning letter with regards to its facility in the US.

During the first half (April-September) of current fiscal 2013-14, the contract manufacturing operations at Jubilant HollisterStier, Spokane contributed 7% to consolidated sales and 4% to consolidated EBITDA of the company, Jubilant Life Sciences said in a regulatory filing.

The company said, until all corrections have been completed and that they have confirmed correction of the violations and firm compliance to cGMPs, FDA may withhold approval of new applications or supplements listing Jubilant HollisterStier-Spokane as the drug product manufacturer, FDA specified in the warning letter.

The stock opened at Rs 124 and touched high of Rs 116 on the BSE. A combined around one million shares have changed hands on the counter in early noon deals on the BSE and NSE.
 

More From This Section

First Published: Dec 06 2013 | 10:43 AM IST

Next Story